UroToday
VerifiedOnline/Digital
UroToday publishes evidence-based clinical content that is organized across the site by disease, treatments and guidelines. This educational platform offers written articles, video lectures or discussions and emerging data presented at conferences. The content across the site is developed, organized and presented by leaders across the urology field. Further, UroToday offers a portal providing access to enrolling clinical trials. The Centers of Excellence (CoE) provide state of the art lectures, original articles and research organized by disease and condition and focused on what is known about treatments or what is emerging in clinical care. Each CoE is led by a clinician-editor and invited faculty. Source
Actions
Media Outlet details
| Scope | International, Trade/B2B |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesImpact of Treatment Intensification with Abiraterone on Fracture-related Hospitalisation in Newly Diagnosed Prostate Cancer: A Secondary Analysis of Two Randomised Phase 3 Trials Within the STAMPEDE Trial Platform.
Prostate cancer (PCa) patients are at increased fracture risk due to the need for androgen deprivation therapy (ADT) and progressive bone metastases. Previous meta-analyses of randomised controlled trials suggest that androgen receptor pathway inhibitors (ARPIs) increase fracture risk. We assessed the impact of abiraterone-based treatment intensification on fracture-related hospitalisation (FRH) within the STAMPEDE trial platform.
Dose-intensified PSMA Radioligand Therapy: The Rationale Behind the OPTIMAL-PSMA Trial - Beyond the Abstract
PSMA-targeted radioligand therapy (PSMA-RLT) has changed the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC), with 177Lu-PSMA now established as a standard treatment following the VISION and TheraP trials. However, current standard dosing schedules – typically 6.0–7.4 GBq every six weeks for up to six cycles - are based on an early adopted estimated safe dose modelled on external beam radiotherapy (EBRT), subsequently shown to be inaccurate and overly conservative.
PSMA PET/CT-guided salvage elective nodal radiotherapy for nodal metastases after radical prostatectomy: a bi-institutional long-term outcome analysis.
PSMA PET/CT has transformed the detection of nodal recurrence after radical prostatectomy, yet real-world evidence on long-term outcomes of PSMA PET/CT-guided salvage elective nodal radiotherapy (ENRT) remains limited. This study evaluated oncological outcomes of PSMA PET/CT-guided salvage ENRT in a bi-institutional cohort with extended follow-up.
Interstitial pneumonia signals of apalutamide, darolutamide, and enzalutamide in FAERS and JADER.
Apalutamide, darolutamide, and enzalutamide are widely used androgen receptor signaling inhibitors (ARSIs) for prostate cancer. Although their clinical benefits are established, interstitial pneumonia remains an uncommon but potentially serious pulmonary adverse event that is insufficiently characterized in routine practice. We conducted a retrospective pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report database (JADER).
Comparative assessment of METastasis Reporting and Data System for Prostate Cancer versus Prostate Cancer Clinical Trials Working Group 3 Criteria in assessing treatment response in patients with metastatic castration-resistant prostate cancer.
Unequivocal clinical progression without radiological progression according to Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria is recognised in metastatic castration-resistant prostate cancer (mCRPC), reflecting limitations of bone scintigraphy in distinguishing an osteoblastic progression from an osteoblastic flare.
[177Lu] Lu-PSMA-I&T for prostate cancer radioligand therapy: A radiopharmacy's journey from synthesis to cost-effectiveness.
Radioligand therapy (RLT) with [177Lu]-Lu-radiolabeled pharmaceuticals targeting PSMA is a promising treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC), with the potential to improve outcomes and quality of life. However, the introduction of these innovative therapies into standard clinical practice presents significant challenges for public hospitals, especially in terms of cost management and sustainability.
Frailty and [177Lu]Lu-PSMA-617 therapy: tools and strategies for older men with metastatic castration-resistant prostate cancer.
The prognosis of metastatic castration-resistant prostate cancer is dismal. [177Lu]Lutetium-prostate-specific membrane antigen (PSMA)-617 ([177Lu]Lu-PSMA-617) is the new standard of care for PSMA-positive mCRPC previously treated with ARPI and taxane-based chemotherapy. The efficacy and safety of [177Lu]Lu-PSMA-617 have been confirmed by phase 2 (TheraP [NCT03392428]) and phase 3 (VISION study [NCT02511664] and PSMAfore trial [NCT04689828]) clinical trials.
Phase 1 Study of Darlifarnib Combined with Cabozantinib in Advanced RCC - Adanma Ayanambakkam
Pedro Barata: Hello everyone. My name is Pedro Barata. I'm a GU oncologist here with UroToday and happy to cover important relevant data being presented at IKCS, which is really emerging in one of the important kidney cancer-related meetings in the country. And today I'm very happy to be joined by my colleague, Dr. Adanma Ayanambakkam. And he's a GU oncologist out of University of Oklahoma, associate program director for the Hemo Fellowship there, doing a great job with clinical trials there.
Low-Dose Finasteride and Its Impact on Semen Parameters and Hormonal Balance - Nilson Marquardt Filho
Alan Wein: Hello again. It's Alan Wein from the Functional Urology Center of Excellence of UroToday, and today we have the special pleasure of talking to Dr. Nilson Marquardt Filho, who is a fellow in sexual medicine and infertility in Sao Paulo, Brazil.
Generative AI Use in Urology Residency Personal Statements - Jay Dalvi & Timothy Lyon
Sam Chang: Hi, I'm Sam Chang. I'm a urologic surgeon who focuses on cancer practice at Vanderbilt University Medical Center, Nashville, Tennessee. Today, we actually have Dr. Tim Lyon, who's the associate professor of urology at Mayo in Jacksonville, Florida. And importantly is the residency program director for that excellent program and one of the leading ones in the Southeast.